Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Current Assets (2016 - 2025)

Corcept Therapeutics (CORT) has disclosed Current Assets for 14 consecutive years, with $485.5 million as the latest value for Q4 2025.

  • Quarterly Current Assets rose 2.94% to $485.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $485.5 million through Dec 2025, up 2.94% year-over-year, with the annual reading at $485.5 million for FY2025, 2.94% up from the prior year.
  • Current Assets hit $485.5 million in Q4 2025 for Corcept Therapeutics, down from $541.1 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $560.8 million in Q2 2024 to a low of $266.5 million in Q4 2021.
  • Historically, Current Assets has averaged $450.8 million across 5 years, with a median of $447.8 million in 2022.
  • Biggest five-year swings in Current Assets: tumbled 44.31% in 2021 and later skyrocketed 87.36% in 2022.
  • Year by year, Current Assets stood at $266.5 million in 2021, then surged by 87.36% to $499.3 million in 2022, then dropped by 8.14% to $458.6 million in 2023, then rose by 2.83% to $471.6 million in 2024, then grew by 2.94% to $485.5 million in 2025.
  • Business Quant data shows Current Assets for CORT at $485.5 million in Q4 2025, $541.1 million in Q3 2025, and $443.1 million in Q2 2025.